Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.0K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.4K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.4K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

36
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
36
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

275
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
275
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

17
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
17
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

238
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
238

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Access to care for adults living with spinal muscular atrophy in the UK.

BMJ neurology open·2026
Same author

Assessing the diagnostic utility of baseline creatine kinase levels in patients with suspected idiopathic inflammatory myopathies and neuromuscular disorders.

Rheumatology advances in practice·2026
Same author

International IVIg prescription patterns in idiopathic inflammatory myopathies: real-world insights from the MyoNet survey.

EULAR rheumatology open·2026
Same author

Health inequalities in outpatient neurological conditions across a large UK urban population: a retrospective observational study using automated coding.

BMJ neurology open·2026
Same author

Assessing the diagnostic performance of the muscle biopsy features in the 2024 ENMC Inclusion Body Myositis Criteria.

Rheumatology (Oxford, England)·2026
Same author

Operant Approach Activity Pacing Interventions for the Management of Chronic Pain: A Systematic Review.

The Clinical journal of pain·2026
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: Sep 17, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.5K

Rituximab for myasthenia gravis.

Katherine C Dodd1,2, Fiona J Clay3, Anne-Marie Forbes4

  • 1Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford, UK.

The Cochrane Database of Systematic Reviews
|July 3, 2025
PubMed
Summary
This summary is machine-generated.

Rituximab likely reduces relapses in myasthenia gravis (MG) but its long-term effects on symptom severity and serious adverse events remain uncertain. Further research is needed to clarify optimal use in MG treatment.

More Related Videos

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

18.6K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Related Experiment Videos

Last Updated: Sep 17, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.5K
Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

18.6K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Area of Science:

  • Autoimmune diseases
  • Neuromuscular disorders
  • Pharmacological interventions

Background:

  • Myasthenia gravis (MG) is an autoimmune condition causing muscle weakness due to impaired neuromuscular transmission.
  • Rituximab is increasingly used for MG, but its efficacy, optimal dosing, and patient subgroups benefiting remain unclear.
  • High-quality evidence is needed to integrate rituximab into MG treatment algorithms.

Purpose of the Study:

  • To assess the effects of rituximab, including biosimilar variants, in adult patients with myasthenia gravis.
  • To evaluate the benefits and harms of rituximab across different patient subgroups and treatment strategies.
  • To inform clinical decision-making and healthcare policy regarding rituximab use in MG.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) and quasi-RCTs.
  • Searched multiple databases (CENTRAL, MEDLINE, Embase) and trials registries up to November 2024.
  • Included adults (≥16 years) with MG, comparing rituximab to placebo, no treatment, or alternative therapies.

Main Results:

  • Two RCTs with 99 participants were included, with differing rituximab dosing strategies.
  • Rituximab likely reduces relapses requiring rescue therapy over nine months (moderate-certainty evidence).
  • Long-term effects on symptom severity, functional ability, and serious adverse events are uncertain (very low-certainty evidence).

Conclusions:

  • Long-term efficacy of rituximab for symptom severity and functional ability in MG is uncertain.
  • Rituximab shows little to no steroid-sparing effect but significantly reduces relapses over nine months.
  • Insufficient data exist to determine optimal dosing or patient characteristics; further research is warranted.